We show that these inhibitors suppress SLC15A4-mediated endolysosomal TLR and NOD functions in a variety of human and mouse immune cells; we offer proof of their capability to suppress inflammation in vivo and in clinical settings; and we offer insights into their system of action. Our findings establish SLC15A4 to be a druggable concentrate on for